SG11202105358RA - Gaboxadol for reducing risk of suicide and rapid relief of depression - Google Patents

Gaboxadol for reducing risk of suicide and rapid relief of depression

Info

Publication number
SG11202105358RA
SG11202105358RA SG11202105358RA SG11202105358RA SG11202105358RA SG 11202105358R A SG11202105358R A SG 11202105358RA SG 11202105358R A SG11202105358R A SG 11202105358RA SG 11202105358R A SG11202105358R A SG 11202105358RA SG 11202105358R A SG11202105358R A SG 11202105358RA
Authority
SG
Singapore
Prior art keywords
gaboxadol
suicide
depression
reducing risk
rapid relief
Prior art date
Application number
SG11202105358RA
Other languages
English (en)
Inventor
Pavel Osten
Kristin Baldwin
Original Assignee
Certego Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Certego Therapeutics filed Critical Certego Therapeutics
Publication of SG11202105358RA publication Critical patent/SG11202105358RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202105358RA 2018-11-21 2019-11-21 Gaboxadol for reducing risk of suicide and rapid relief of depression SG11202105358RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770287P 2018-11-21 2018-11-21
PCT/US2019/062554 WO2020106927A1 (en) 2018-11-21 2019-11-21 Gaboxadol for reducing risk of suicide and rapid relief of depression

Publications (1)

Publication Number Publication Date
SG11202105358RA true SG11202105358RA (en) 2021-06-29

Family

ID=70728606

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105358RA SG11202105358RA (en) 2018-11-21 2019-11-21 Gaboxadol for reducing risk of suicide and rapid relief of depression

Country Status (13)

Country Link
US (3) US20220008398A1 (zh)
EP (1) EP3883566A4 (zh)
JP (1) JP2022514194A (zh)
KR (1) KR20210110585A (zh)
CN (1) CN113395962A (zh)
AU (1) AU2019384157A1 (zh)
BR (1) BR112021009944A2 (zh)
CA (1) CA3120856A1 (zh)
GB (1) GB2594616A (zh)
IL (1) IL283311A (zh)
MX (1) MX2021005992A (zh)
SG (1) SG11202105358RA (zh)
WO (1) WO2020106927A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
EP3883566A4 (en) * 2018-11-21 2022-09-07 Certego Therapeutics Inc. GABOXADOL FOR SUICIDE RISK REDUCTION AND RAPID DEPRESSION RELIEF
CA3182508A1 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
TW200509918A (en) 2003-06-25 2005-03-16 Lundbeck & Co As H Treatment of depression and other affective disorders
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
CL2004001603A1 (es) * 2003-06-25 2005-05-27 Lundbeck & Co As H Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico.
TW200501951A (en) 2003-06-25 2005-01-16 Lundbeck & Co As H Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
ES2341004T3 (es) 2003-06-25 2010-06-14 H. Lundbeck A/S Gaboxadol para tratar la depresion y otros trastornos afectivos.
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
US20050137222A1 (en) 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
CN1942185A (zh) 2004-04-02 2007-04-04 H.隆德贝克有限公司 用加波沙朵治疗呼吸功能损伤
EP1734956A1 (en) 2004-04-02 2006-12-27 H.Lundbeck A/S Treatment of impaired respiratory function with gaboxadol
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
US8022084B2 (en) 2005-01-28 2011-09-20 H. Lundbeck A/S Polymorphic forms of a GABAA agonist
EP1906953A4 (en) 2005-04-29 2009-05-20 Lundbeck & Co As H FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20080159958A1 (en) * 2006-12-27 2008-07-03 Abbott Laboratories Determination of histamine-3 bioactivity
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
GB0810063D0 (en) 2008-06-03 2008-07-09 Renovo Ltd Medicaments and methods for inhibition of scarring
JP2012501301A (ja) 2008-09-01 2012-01-19 ハー・ルンドベック・アクチエゼルスカベット ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物
US11083732B2 (en) * 2014-03-31 2021-08-10 University Of Maryland, Baltimore Use of negative modulators of GABA receptors containing alpha5 subunits as fast acting antidepressants
WO2015171547A1 (en) 2014-05-05 2015-11-12 Ovid Therapeutics Inc. Methods of treating cognitive impairment associated with neurodegenerative disorders
HUE055155T2 (hu) 2014-06-06 2021-11-29 Ovid Therapeutics Inc Módszerek a tónusos gátlás növelésére és a másodlagos álmatlanság kezelésére
WO2016057533A1 (en) 2014-10-06 2016-04-14 Ghaemi Seyyed Nassir Primary and secondary prevention of dementias and suicide with trace dose lithium
CA2977437C (en) 2015-03-24 2023-07-04 H. Lundbeck A/S Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol
US20160317477A1 (en) 2015-04-30 2016-11-03 Ovid Therapeutics Inc. Methods of treating prader-willi syndrome
AR105378A1 (es) 2015-07-17 2017-09-27 Ovid Therapeutics Inc Métodos de tratamiento de trastornos del desarrollo con gaboxadol
US9682069B2 (en) * 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
KR20180031721A (ko) 2015-07-17 2018-03-28 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
AR105670A1 (es) 2015-08-11 2017-10-25 Ovid Therapeutics Inc Métodos de sedación parenteral para usar durante el tratamiento de cuidados intensivos
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
KR20180048707A (ko) 2015-08-11 2018-05-10 오비드 테라퓨틱스 인크. 중환자 치료 동안 사용을 위한 진정제 및 비경구 제제의 방법들
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
US20170119704A1 (en) 2015-10-13 2017-05-04 Ovid Therapeutics Inc. Treatment of cognitive impairment
MX2018013973A (es) 2016-05-26 2019-03-28 Ovid Therapeutics Inc Metodos de tratamiento de sindromes de comportamiento usando pipradrol.
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
EP3528807A4 (en) 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
US10737984B2 (en) 2016-11-30 2020-08-11 Hrl Laboratories, Llc Formulations and methods for 3D printing of ceramic matrix composites
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20190060400A1 (en) 2017-03-15 2019-02-28 Ovid Therapeutics Inc. Use of designer receptors exclusively activated by designer drugs and ultrasound in the treatment of seizure disorders
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
WO2018222957A1 (en) 2017-06-01 2018-12-06 Ovid Therapeutics Inc. Treatment of developmental disorders with imidazolone derivatives
US20190000993A1 (en) 2017-06-28 2019-01-03 Ovid Therapeutics Inc. Treatment of developmental syndromes
WO2019028234A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
AU2018320849A1 (en) 2017-08-25 2020-03-05 Ovid Therapeutics Inc. Recombinant adeno-associated vectors
US20190076409A1 (en) 2017-09-12 2019-03-14 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of narcolepsy
CN107595850A (zh) 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种有效提高睡眠质量的药物组合物及其用途
KR20210039324A (ko) 2018-04-06 2021-04-09 오비드 테라퓨틱스 인크. 물질 사용 장애들의 치료에서 가복사돌의 사용
EP3883566A4 (en) * 2018-11-21 2022-09-07 Certego Therapeutics Inc. GABOXADOL FOR SUICIDE RISK REDUCTION AND RAPID DEPRESSION RELIEF

Also Published As

Publication number Publication date
EP3883566A1 (en) 2021-09-29
MX2021005992A (es) 2021-09-14
AU2019384157A1 (en) 2021-06-17
CA3120856A1 (en) 2020-05-28
IL283311A (en) 2021-07-29
WO2020106927A1 (en) 2020-05-28
GB202108720D0 (en) 2021-08-04
JP2022514194A (ja) 2022-02-10
GB2594616A (en) 2021-11-03
US11123332B2 (en) 2021-09-21
KR20210110585A (ko) 2021-09-08
US20220008398A1 (en) 2022-01-13
US20220054461A1 (en) 2022-02-24
CN113395962A (zh) 2021-09-14
EP3883566A4 (en) 2022-09-07
BR112021009944A2 (pt) 2021-08-17
US20200155522A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
IL283311A (en) Goxadol for reducing the risk of suicide and rapid relief from depression
EP3700527A4 (en) PAPD5 INHIBITORS AND THEIR METHODS OF USE
EP3684364A4 (en) PYRIDAZINONE AND METHOD OF USE THEREOF
EP3454945A4 (en) ASH1L INHIBITORS AND METHODS OF TREATMENT THEREOF
EP4072576A4 (en) IL-2 ORTHOLOGIST AND APPLICATION METHOD
EP3618807A4 (en) COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS
EP3810617A4 (en) Ectonucleotidase inhibitors and methods of use thereof
EP3870162A4 (en) SSAO INHIBITORS AND USES THEREOF
EP3706737A4 (en) ASH11 INHIBITORS AND METHOD OF TREATING THEREOF
EP3962479A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
EP3962481A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
EP3710430A4 (en) ACSS2 INHIBITORS AND THEIR PROCEDURES FOR USE
EP3481393A4 (en) COMBINATION OF A PD-1 ANTAGONIST AND A RAF INHIBITOR FOR THE TREATMENT OF CANCER.
EP3852533A4 (en) PYRIDAZINONES AND THEIR METHODS OF USE
EP3720439A4 (en) NSD FAMILY INHIBITORS AND TREATMENT METHODS INCLUDING THESE
EP3471763A4 (en) COMPOSITIONS FOR CONTROLLING TUBERCULOSIS AND METHODS OF TREATING OR PREVENTING TUBERCULOSIS
EP3576766A4 (en) CYCLIN-G1 INHIBITORS AND RELATED METHODS FOR TREATING CANCER
EP3635000A4 (en) MANABODIES AND METHODS OF USE
EP3846808A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
EP4034219A4 (en) DEVICES AND METHODS FOR INTERSTITIAL DECONGESTION
EP3781168A4 (en) PAK4 INHIBITORS AND METHODS OF USE
EP3761989A4 (en) IMIDAZODIAZEPINEDIONES AND THEIR METHODS FOR USE
EP3649240A4 (en) RNAI ALPHA-ENaC GENE EXPRESSION INHIBITION AGENTS AND METHODS OF USE
EP3844208A4 (en) CYANINE-BASED TELODENDRIMERS AND USES IN THE TREATMENT OF CANCER
EP3718356A4 (en) SECONDARY CELL CONTROL PROCESS AND APPARATUS